Umecrine Cognition Overview

  • Founded
  • 2006

Founded
  • Status
  • Private

  • Employees
  • 3

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.1M

  • Investors
  • 5

Umecrine Cognition General Information

Description

Developer of pharmaceutical products designed to treat cognitive neurological disorders. The company's pharmaceutical products focus on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids), enabling healthcare industries to provide treatment that directly addresses the neurocognitive signs and symptoms of Hepatic encephalopathy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Karolinska Institutet Science Park
  • Fogdevreten 2
  • 171 65 Solna
  • Sweden
+46 073-039 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Umecrine Cognition Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 14-Jul-2021 $4.1M 000.00 Completed Clinical Trials - Phase 2
3. Later Stage VC 04-Oct-2017 00.000 00.000 Completed Clinical Trials - Phase 2
2. Later Stage VC 22-Nov-2016 $4.96M $4.96M Completed Clinical Trials - Phase 2
1. Early Stage VC Completed Startup
To view Umecrine Cognition’s complete valuation and funding history, request access »

Umecrine Cognition Patents

Umecrine Cognition Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3083555-A1 Pharmaceutical formulation of 3.alpha.-ethynyl-3.beta.-hydroxyandrostan-17-one oxime Pending 27-Nov-2017 0000000000
AU-2018374029-A1 Pharmaceutical formulation of 3a-ethynyl-3b-hydroxyandrostan-17-one oxime Pending 27-Nov-2017 0000000000
US-20190358244-A1 Pharmaceutical formulation of 3alpha -ethynyl-3beta-hydroxyandrostan-17-one oxime Granted 27-Nov-2017 0000000000
JP-2021504468-A Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostane-17-onoxime Pending 27-Nov-2017 0000000000
US-11123351-B2 Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime Active 27-Nov-2017 A61K9/4858
To view Umecrine Cognition’s complete patent history, request access »

Umecrine Cognition Executive Team (5)

Name Title Board Seat Contact Info
Torbjörn Bäckström MD Founder, Co-Chief Executive Officer & Board Member
Magnus Doverskog Ph.D Co-Chief Executive Officer
Hans Toll Chief Financial Officer
Lars Öhman Chief Business Officer
Eva Arlander Ph.D Chief Development Officer
To view Umecrine Cognition’s complete executive team members history, request access »

Umecrine Cognition Board Members (6)

Name Representing Role Since
Bruce Scharschmidt Ph.D Umecrine Cognition Board Member 000 0000
John Öhd Ph.D Karolinska Development Board Member 000 0000
Kenth Bergström Self Board Member 000 0000
Thomas Blackburn Ph.D Umecrine Cognition Board Member 000 0000
Torbjörn Bäckström MD Umecrine Cognition Founder, Co-Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Umecrine Cognition Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Umecrine Cognition Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Almi Invest Venture Capital Minority 000 0000 000000 0
Fort Knox Förvaring Holding Company Minority 000 0000 000000 0
Karolinska Development Venture Capital Minority 000 0000 000000 0
Norrlandsfonden Lender/Debt Provider Minority 000 0000 000000 0
Partnerinvest Norr Venture Capital Minority 000 0000 000000 0
To view Umecrine Cognition’s complete investors history, request access »